Frederico Costa, President and Founder of Autem Medical, attended the ESMO Congress 2019 and presented Autem Medical’s results with the poster Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various EORTC-C30 analyses.
We are developing a medical device we believe, based on promising studies, is a unique and disruptive new solution for treating cancer.
In feasibility and proof of concept studies involving patients with HCC, improved quality of life and extended overall survival has been observed.
Based on our positive studies, the Autem gEM device will offer a non-toxic and non-invasive new treatment option for patients with advanced cancer. Our treatment consists in applying patient-specific frequencies (PSF) to patients with advanced cancer either as monotherapy or in conjunction with standard treatment (add-on therapy) positively impacting the patient’s quality of life and extension in survival.
This new medical device has not yet received regulatory approval and is not available for commercial distribution.
Based on promising studies, we are developing a medical device we believe will be a non-invasive, non-toxic, patient-specific option for treating cancer.
We are a biotechnology company. Our team consists of physician-scientists and scientists from various fields of science with the same mission: the development of better, scientifically proven, and innovative technological strategies for the diagnosis and treatment of patients with various cancer types.
The Autem technology is consistent with current and future healthcare trends that combine technology and artificial intelligence to create better healthcare for patients at risk of, or already diagnosed with, cancer.
Autem’s innovative technology is scientifically based on clinical trials and research conducted by renowned researchers and physicians worldwide.